Psychedelic Clinical Trials & Who’s Behind Them
February 18th, 2021
Psychedelics, Top Story
The psychedelics industry has experienced unprecedented growth over the past few years, driven by a combination of emerging research, regulatory support and investor interest. With a growing number of organizations in the space, it can be difficult for investors to keep track of what clinical trials are ongoing and what opportunities lie in the horizon.
Let’s take a look at some clinical trials taking place across therapeutic areas and how investors can participate in the potential upside.
Clinical Trials Across Therapeutic Areas
The FDA has taken an increasingly accommodative approach to psychedelic medicines as a growing body of research suggests that it could help treat many different conditions. In addition to “breakthrough therapy designations” for several trials, the FDA approved Spravato—a ketamine-based nasal spray for depression in March 2019.
The most significant clinical trials in the space include:
- MAPS is running a Phase III clinical trial evaluating MDMA for the treatment of post-traumatic stress disorder (PTSD). The organization also has several other clinical trials evaluating anxiety and other disorders in Phase II clinical trials.
- COMPASS is evaluating a psychedelic treatment for treatment-resistant depression (TRD) with a Phase II clinical trial of its COMP360 program.
- The Usona Institute has a Phase II clinical trial evaluating psilocybin for the treatment of major depressive disorder (MDD).
- Mind Medicine Inc. (NEO: MMED) is running several Phase II clinical trials evaluating LSD for the treatment of anxiety, cluster headaches and ADHD.
- Awakn Life Sciences has a Phase II clinical trial evaluating MDMA for alcohol addiction.
- Seelos Therapeutics is evaluating psychedelic therapies for the treatment of acute suicidal ideations in major depressive disorder with its SLS-002 program.
- Eleusis’ ELE-Ket+ is in Phase II clinical trials for the treatment of major depressive disorder as an adjunctive treatment.
There are several other companies running earlier stage clinical programs or gearing up to begin clinical trials, including many publicly traded companies. In some cases, these companies could present attractive opportunities since the market hasn’t fully valued the opportunity. Investors may want to take a look at them as a way to diversify exposure in the space.
Building a Unique Psychedelics Platform
Most clinical studies are focused on mental health disorders, psychedelic medicine could play a much larger role in unmet medical conditions, like neuropsychiatric diseases, chronic pain, rare diseases and eating disorders among other things. In addition, many companies are pursuing clinical trials using off-the-shelf compounds.
Tryp Therapeutics (CSE: TRYP) is a pharmaceutical company focused on identifying and developing clinical stage compounds for diseases with high unmet medical needs through accelerated regulatory pathways. Through its PFN™ platform, the company is developing psilocybin-based drug therapies for certain neuropsychiatric disorders.
Click here to learn more about investing in Tryp Therapeutics
Tryp Therapeutics’ Clinical Pipeline – Source: Visual Capitalist
The company’s primary focus is on Fibromyalgia, a chronic pain syndrome affecting up to 400 million people around the world that’s characterized by abnormal processing by the central nervous system. With existing therapies leading to inconsistent responses and side effects, nearly a third of patients take chronic opioids despite the risks.
In addition to Fibromyalgia, the company is evaluating psychedelic treatments for eating disorders and other neuropsychiatric disorders. The market for psychedelics treatments as a whole could grow from $2 billion in 2019 to $6.8 billion by 2026, according to Data Bridge Market Research, creating blue-sky potential over the coming years.
Click here to learn more about investing in Tryp Therapeutics
Investors interested in psychedelics have a growing number of opportunities as companies advance their clinical trials. While there are a handful of companies in Phase II and III clinical trials, investors should pay close attention to emerging players that could offer broader platforms and/or a more targeted focus to the market.
For more information about Tryp Therapeutics, visit the company’s website or download their investor presentation.
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.